<DOC>
	<DOCNO>NCT03036852</DOCNO>
	<brief_summary>The primary objective study evaluate safety , efficacy tolerability treatment sofosbuvir ( Sovaldi® ) /velpatasvir ( Epclusa® ; SOF/VEL ) 12 week adults chronic hepatitis C virus ( HCV ) infection dialysis End Stage Renal Disease ( ESRD ) .</brief_summary>
	<brief_title>Sofosbuvir/Velpatasvir Adults With Chronic Hepatitis C Virus Infection Who Are Dialysis End Stage Renal Disease</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Key Chronic HCV infect , male nonpregnant/nonlactating female age 18 year old dialysis ESRD , include adult HIV coinfection suppress stable , protocolapproved antiretroviral ( ARV ) regimen ≥8 week prior screen . NOTE : Other protocol define Inclusion/ Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>